Article: Data Show That LUNESTA(TM) May Be Cost Effective for Treating Chronic Insomnia.

MARLBOROUGH, Mass., May 17 /PRNewswire-FirstCall/ -- Sepracor Inc. announces the presentation of results from two analyses designed to assess potential pharmacoeconomic benefits associated with the use of LUNESTA(TM) brand eszopiclone in the long-term treatment of insomnia. LUNESTA is the first and only sleep aid approved by the U.S. Food and Drug Administration (FDA) for long-term use. These data were presented yesterday at the 10th Annual International Society for Pharmacoeconomics and Outcomes Research Meeting (ISPOR) held in Washington, DC.

Forecasting the Impact of Adding a New Drug on Formulary Using Medical Claims Data and Clinical Literature: A Case Study of ...

Related newspaper, magazine, and journal articles:

Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!